Resonance Health (RHT.AX) Aandeel Koers
Resonance Health Koers
De omzet is de afgelopen 19 jaar met 11,9% per jaar gegroeid tot 15,75 Miljoen AUD. De winst per aandeel is de afgelopen 17 jaar met 3,8% per jaar gegroeid. De nettowinstmarge van Resonance Health ligt op 9,6% en is ten opzichte van -29,8% enkele jaren eerder gestegen.
Resonance Health aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Resonance Health bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Resonance Health
The business model of Resonance Health Ltd focuses on providing innovative medical imaging software and services. The company aims to improve patient care and outcomes through its advanced technology solutions. Resonance Health specializes in the development and commercialization of non-invasive diagnostic tools, particularly in the field of liver and cardiac diseases. By leveraging its expertise in quantitative analysis and iron overload assessment, Resonance Health offers reliable and efficient solutions for diagnosing and managing various health conditions. The company operates by licensing its software to medical institutions and partnering with healthcare providers, ensuring widespread accessibility and utilization of its cutting-edge technologies.
Resonance Health Ltd is primarily active in the healthcare and medical technology industries.
The main competitors of Resonance Health Ltd in the market include other companies operating in the medical diagnostics and healthcare sector. Some prominent competitors are InHealth Group, Q BioMed, and Novartis AG. Resonance Health Ltd faces competition from these companies in developing innovative diagnostic solutions and providing high-quality healthcare services.
Resonance Health Ltd. is a leading provider of automated, non-invasive medical imaging software and analysis services. Founded in 1987, the company has a rich history of innovation and expertise in the field of liver and cardiac MRI imaging. Resonance Health's technology allows for accurate and reliable diagnosis of liver iron concentration and cardiac ejection fraction, essential measurements for monitoring patients with iron overload and heart conditions. With a strong commitment to research and development, Resonance Health continues to develop cutting-edge solutions that improve patient outcomes and streamline healthcare processes. As a trusted name in the industry, Resonance Health Ltd. has gained recognition globally for its advanced medical imaging products and services.
Resonance Health Ltd, a leading company in the healthcare sector, has accomplished several significant milestones. One noteworthy achievement is the development of FerriScan®, an advanced diagnostic tool for measuring liver iron concentration. Through extensive research and innovative technology, Resonance Health Ltd has revolutionized the diagnosis and monitoring of iron overload disorders such as hereditary hemochromatosis and thalassemia. The company has also expanded its global presence by establishing partnerships with renowned medical institutions and securing regulatory approvals for its groundbreaking products. With a relentless commitment to advancing patient care, Resonance Health Ltd continues to make remarkable strides in the field of medical diagnostics.
Resonance Health Ltd is primarily present in multiple countries and regions across the world. With its global reach, the company has established a strong presence in key markets. Its operations span across Australia, the United States, Europe, and Asia-Pacific regions. Resonance Health Ltd's commitment to expanding its footprint internationally has enabled it to serve a diverse range of customers and collaborate with partners on a global scale. This global presence reinforces Resonance Health Ltd's position as a leading player in the industry while allowing it to leverage various market opportunities and better serve its stakeholders.
Resonance Health Ltd represents values of innovation, excellence, and integrity in its corporate philosophy. As a leading stock health company, Resonance Health Ltd focuses on utilizing advanced technology and research to improve the diagnosis and treatment of liver diseases and iron disorders. With a dedicated team of experts, the company prioritizes accuracy and efficiency in its solutions, delivering reliable results to healthcare professionals worldwide. Resonance Health Ltd strives to enhance patient care by providing precise diagnostic tools, earning recognition for its commitment to quality and advancing medical knowledge.
Omgezet tegen de huidige wisselkoers noteert het aandeel Resonance Health op 0,04 EUR (0,07 AUD).
Het aandeel Resonance Health (RHT.AX) is genoteerd aan 1 beurzen, waaronder: ASX (RHT.AX).
Resonance Health Ltd is a medical technology and software company specializing in the development and marketing of medical imaging devices, software, and services. The company is based in Perth, Australia, and operates worldwide.
De omzet van Resonance Health bedraagt 15,75 Miljoen AUD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van Resonance Health bedraagt 1,51 Miljoen AUD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Resonance Health bedraagt momenteel 21,41. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Resonance Health-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Resonance Health bedraagt momenteel 2,06. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Resonance Health-aandeel.
De Eulerpool Kwaliteitsscore voor Resonance Health is 5/10.
De ISIN van Resonance Health is AU000000RHT2. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Resonance Health is A0BK8V. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Resonance Health is RHT.AX. Onder dit beurstickersymbool wordt het Resonance Health-aandeel op de beurs verhandeld.
Resonance Health aandeel
Resonance Health Peer Group
Resonance Health Ticker
Resonance Health FIGI
Alle fundamentals en diepgaande analyse van Resonance Health
Onze aandelenanalyse van het Resonance Health-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Resonance Health. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: